Needham & Company Maintains a 'Buy' on Aastrom Biosciences (ASTM); SPA in the Summer Worth the Wait - Phase 3 Stem Cell Ixmyelocel-T Trial
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Aastrom Biosciences (NASDAQ: ASTM) price target $6.
Needham analyst says, "This morning, Aastrom ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "This morning, Aastrom ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
